Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Investigation
NEW YORK, NY / ACCESSWIRE / July 21, 2021 / July Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Investors who purchasedMagenta shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mgta.
The investigation concerns whether Magentaand certain of its officers and/or directors have violated federal securities laws.
On July 21, 2021, Magenta issued a press release "announc[ing] that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)." Magenta stated that "[t]he FDA is requiring that Magenta develop an additional bioassay to be used in conjunction with the PK/PD model to inform dose escalation decisions in addition to safety monitoring." On this news, Magenta's stock price fell sharply during intraday trading on July 21, 2021.
If you are aware of any facts relating to this investigation, or purchased Magentashares, you can assist this investigation by visiting the firm's site: www.bgandg.com/mgta. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/656536/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-Magenta-Therapeutics-Inc-NASDAQMGTA-Investigation
